TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04308837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 given by intravenous infusion on days 1, 8, 15, 22 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 2 given by intravenous infusion on days 1, 8, 15, 22 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: All patients receiving Paclitaxel will receive institutional standard premedications, which include Dexamethasone (10 mg IVPB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: All patients receiving Paclitaxel will receive institutional standard premedications, which include diphenhydramine (50mg IVP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: All patients receiving Paclitaxel will receive institutional standard premedications, which include Famotidine (20mg IVPB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: All patients receiving Paclitaxel will receive institutional standard premedications, which include Palonosetron (0.25mg IVP)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal or intensity modulated radiotherapy
Description: Treatment will be given 5 days per week. Photon beams \>6 MV are required. Treatment may be delivered either by a 3D conformal technique or IMRT. IMRT via dynamically moving MLCs, step-and-shoot with a multileaf collimator, Rapid Arc, binary multileaf collimator, and tomotherapy are allowed. Proton therapy is not allowed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical resection will constitute subtotal or total gastrectomy (depending on tumor size and location) and D2 lymphadenectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: The patient will begin adjuvant chemotherapy 4-12 weeks after surgery. The adjuvant chemotherapy will consist of FOLFOX every 2 weeks for 6 cycles (i.e. 3 months)
Study: NCT03583138

Intervention type: DRUG
Intervention: buprenorphine
Description: To provide buprenorphine for 12 months for those who are interested in receiving it.
Study: NCT03879044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
Study: NCT03790358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: Drug will be administered in solution form.
Study: NCT01603797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered acceptance and commitment therapy
Description: The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided internet-delivered acceptance and commitment therapy
Description: The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
Study: NCT02687347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Description: Oral morphine is the active comparator. It is not a placebo intervention
Study: NCT01464632

Intervention type: DEVICE
Intervention: EPIK™ uni-compartmental knee
Description: This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
Study: NCT02117739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Study: NCT03688698

Intervention type: RADIATION
Intervention: PET/MRI
Description: PET/MRI scans

Intervention type: RADIATION
Intervention: PET/MRI
Description: PET/MRI scans
Study: NCT00841048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4017
Description: ascending multiple doses(start dose 75mg od), oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01328041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Description: 50 mg twice daily
Study: NCT02446470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus Tarsi approach
Description: A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensile Lateral approach
Description: An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
Study: NCT02968381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Intervention
Description: Telephone coaching sessions, use of guided imagery and website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Telephone coaching using standard cognitive behavioral methods
Study: NCT04441164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation of Virtual Actions
Description: If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Relaxation
Description: If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability questionnaire
Description: It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability questionnaire
Description: It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation of Virtual Actions (step 4)
Description: If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performing Virtual Actions
Description: If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptic stimulation
Description: According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
Study: NCT02909504

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels \> 0.6 mEq/L
Study: NCT04441164

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Without haptic stimulation
Description: Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
Study: NCT04436471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: adenoviral-based vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: adenoviral-based vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: adenoviral-based vaccine against SARS-CoV-2
Study: NCT04414124

Intervention type: OTHER
Group type: OTHER
Intervention: KB109 + Self Supportive Care (SSC)
Description: KB109 is a novel glycan

Intervention type: OTHER
Group type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study: NCT03675425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1: non chest shielding
Description: non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 2: chest shielding
Description: chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
Study: NCT02420054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
Study: NCT01366612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
Description: Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1
Study: NCT03262207

Intervention type: OTHER
Intervention: Extraction genomic DNA
Study: NCT02088736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraosseous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous
Study: NCT03262207

Intervention type: OTHER
Intervention: Extraction genomic DNA

Intervention type: OTHER
Intervention: Extraction genomic DNA

Intervention type: OTHER
Intervention: Analysis of methylation profiles of numerous GSI and TE

Intervention type: OTHER
Intervention: Analysis of methylation profiles of numerous GSI and TE

Intervention type: OTHER
Intervention: Analysis of methylation profiles of numerous GSI and TE

Intervention type: OTHER
Intervention: Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)

Intervention type: OTHER
Intervention: Method of protein detection by immunostaining and flow cytometry

Intervention type: OTHER
Intervention: Method of protein detection by immunostaining and flow cytometry

Intervention type: OTHER
Intervention: Method of protein detection by immunostaining and flow cytometry
Study: NCT03562234

Intervention type: DIAGNOSTIC_TEST
Intervention: MR
Description: Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: LiMAx
Description: Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
Study: NCT00751309

Intervention type: OTHER
Intervention: Non-interventional
Description: Post-transplantation observational study
Study: NCT00628589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Description: Inhaled loxapine 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Description: Inhaled loxapine 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled placebo
Study: NCT00308893

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Compare BDNF polymorphism among responders and non-responders
Study: NCT01460719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ
Study: NCT00354107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody SGN-30
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03627065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib administered orally once daily at the protocol-defined dose.
Study: NCT02303782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza (azacitidine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza (azacitidine)
Study: NCT03542916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-40001 60ug
Description: CJ-40001 60ug SC, IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60ug
Description: NESP 60ug SC, IV injection
Study: NCT03470129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fissure sealing
Description: sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fissure sealing
Description: sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
Study: NCT03132519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
Study: NCT04545320

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care control group
Description: Health education
Study: NCT04545320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: Once-a-week HIIT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT group
Description: Once-a-week MICT
Study: NCT03066362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography-Doppler
Description: Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
Study: NCT01960088

Intervention type: DRUG
Intervention: HPV vaccine
Study: NCT03739957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPCO Media Kit
Description: Telemonitoring system for patients with COPD
Study: NCT02830607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiaomi Mi Band
Description: participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
Study: NCT05394532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Common Education
Study: NCT01901679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 200 mg PO BID
Study: NCT02008461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin injection
Study: NCT03819023

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respilife monitor
Description: Respilife monitor
Study: NCT00314028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus on the Future
Description: Focus on the Future is an educational program designed to promote proper condom use.
Study: NCT02420054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time control
Description: Time control period with no change in eating habits.
Study: NCT03336775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
Study: NCT01813084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 single dose
Description: Safety and tolerability of single escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo single dose
Description: Safety and tolerability of single escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses
Study: NCT03509025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jointstem
Description: JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
Study: NCT00877058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preventive home visit
Study: NCT03417700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NW training
Description: NW training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NW training
Description: NW training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NW training
Description: NW training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: training with placebo
Study: NCT00877058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: senior meetings